This heterogeneity in GBM may elucidate the lack of success observed in targeted treatments aimed specifically at tumor biomarkers, including drugs like cetuximab, gefitinib, erlotinib (targeting EGFR), bevacizumab (targeting VEGF), and cilengitide (targeting integrin). This evidence concerns the gene EGFR and neoplasm.